title: Variations in living donor graft rates by dialysis clinic: effect on outcome and cost of chronic renal failure therapy.
abstract: OBJECTIVE
  Examination of nephrology practice variations in living donor renal grafts to determine their influence on organ supply, quality, and cost of chronic renal failure therapy.
  
  
  METHODS
  Saskatchewan chronic dialysis, cadaveric, and living donor renal grafts in 1983-1994 inclusive.
  
  
  RESULTS
  Saskatchewan has three dialysis (I, II, III) and one transplant clinic. In the period the renal graft incidences/million population by these dialysis clinics by organ source were; Cadaveric: 23.1, 23.2, 21.1 (p = ns). Living: 5.4, 21.7, 8.3 (I or III vs II p < 0.000, I vs III p < 0.061). Total: 28.7, 44.7, 29.4. Living donor series A is 79 grafts in patients under age 60 with primary renal disease. Series B is 20 grafts in patients with secondary renal disease or over age 59. Series A ten-year actuarial patient survival is 92% and B 44%. Series A ten-year actuarial graft survival (including regrafts) is 77% and B 39%. Rehabilitation rate in patients with functioning grafts is 88.5%. Province-wide extension of the Clinic II living-donor graft rate in 1983-1994 would have produced 160 more renal grafts or 59% of those receiving chronic dialysis in 1994. The annual maintenance for a graft with the initial grafting cost taken over five years was $10,825 and the dialysis cost $40,100.
  
  
  CONCLUSIONS
  (1) nephrology practice variations caused a 2.5-4.0-fold difference in living donor renal graft rates, indicating patient education by the attending nephrologist influences the living donor transplantation rate, (2) with such education the combined living donor and the cadaveric organ supply virtually meets graft demand, (3) living donor renal grafts yield a better quantity and quality of life and better cost control than dialysis with their annual cost being one-quarter that for dialysis.
authors.affiliation: Baltzan Clinic, Saskatoon, Canada.
authors.forename: M A
authors.initials: MA
authors.lastname: Baltzan
authors.forename: S
authors.initials: S
authors.lastname: Ahmed
authors.forename: R B
authors.initials: RB
authors.lastname: Baltzan
authors.forename: R P
authors.initials: RP
authors.lastname: Marshall
authors.forename: E L
authors.initials: EL
authors.lastname: Thoma
authors.forename: M F
authors.initials: MF
authors.lastname: Nicol
mesh_terms: D000206:Actuarial Analysis; D002102:Cadaver; D003365:Costs and Cost Analysis; D005260:Female; D006085:Graft Survival; D006801:Humans; D007676:Kidney Failure, Chronic / Q000191:economics* / Q000401:mortality / Q000628:therapy*; D016030:Kidney Transplantation / Q000191:economics / Q000706:statistics & numerical data*; D019520:Living Donors / Q000706:statistics & numerical data*; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000191:economics / Q000706:statistics & numerical data*; D006435:Renal Dialysis / Q000191:economics*; D012525:Saskatchewan; D014019:Tissue Donors / Q000706:statistics & numerical data; D016896:Treatment Outcome